Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Protalix
Age
14–45
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Males, age 14-45 years, naïve to enzyme replacement therapy (ERT) or off ERT or off chaperone treatment for at least 6 months and negative for anti-PRX-102 antibodies
A documented diagnosis of Fabry disease: Plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than lower limit of normal (LLN)
eGFR by CKD-EPI \> 30 ml/min/1.73 m2
Moderate to severe gastrointestinal symptoms as defined by:
* Average score of \> 175 from at least two Irritable Bowel Symptom Severity Score (IBSSS) Part 1 assessments before randomization.
* Average stool consistency of ≥ 5.5 on the Bristol Stool Form Scale (BSFS) by patient diary during 2 weeks prior to randomization out of the 4 week of screening period and
* ≥ 3 stools a day with a consistency of ≥ 5 on the BSFS during the week before randomization.
Completed electronic BSFS diary on at least 6 of the 7 days during the week prior to randomization AND at least 11 of the 14 days during the 2 weeks prior to randomization.
You may not be if
Patients will be evaluated to rule out other gastrointestinal comorbidity than Fabry disease as responsible for the gastrointestinal symptoms by:
i. Medical History for non Fabry gastrointestinal comorbidity ii. Occult blood in stool iii. Stool culture for bacteria and parasites iv. Calprotectin in stool v. Sigmoidoscopy
Use of any kind of laxatives
Initiation of anti-diarrheal medications during the screening period
History of renal dialysis or transplantation
Use of, or change in dose of, angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) for less than 4 weeks prior to screening
Cardiovascular event (myocardial infarction, unstable angina) in the 6 month period before randomization
Congestive heart failure NYHA Class IV
Cerebrovascular event (stroke, transient ischemic attack) in the 6 month period before randomization
Known history of hypersensitivity to Gadolinium contrast agent
Known allergies to ERT
Presence of any medical, emotional, behavioral or psychological condition that, in the judgment of the Investigator and/or Medical Director, would interfere with the patient's compliance with the requirements of the study